NASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis $98.96 -0.79 (-0.79%) Closing price 04:00 PM EasternExtended Trading$98.96 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Spyre Therapeutics Stock (NASDAQ:SYRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spyre Therapeutics alerts:Sign Up Key Stats Today's Range$97.95▼$100.4250-Day Range$78.63▼$107.7952-Week Range$21.15▼$110.18Volume567,635 shsAverage Volume1.40 million shsMarket Capitalization$10.09 billionP/E RatioN/ADividend YieldN/APrice Target$110.40Consensus RatingModerate Buy Company Overview Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is centered on engineered antibody therapies designed to provide durable disease control, convenient dosing and improved treatment characteristics. Spyre’s investigational pipeline includes antibody programs directed at important inflammatory pathways, including interleukin-23 (IL-23) and TL1A. Its drug candidates are being developed for potential use as standalone treatments or in combination with other therapies, with the goal of addressing the needs of patients who do not respond adequately to existing IBD medicines. The company was created through a 2023 business combination involving Aeglea Therapeutics and a privately held company also named Spyre Therapeutics. Following the transaction, Aeglea adopted the Spyre Therapeutics name and began trading on the Nasdaq under the symbol SYRE. Spyre is headquartered in the United States and conducts clinical-stage research and development activities for therapies intended for patients with inflammatory diseases.AI Generated. May Contain Errors. Read More Spyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreSYRE MarketRank™: 2.312112603305 of 5 starsSpyre Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 635th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingSpyre Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSpyre Therapeutics has a consensus price target of $110.40, representing about 11.6% upside from its current price of $98.96.Amount of Analyst CoverageSpyre Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.71) to ($3.67) per share.Price to Book Value per Share RatioSpyre Therapeutics has a P/B Ratio of 13.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Spyre Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.56% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 7.34.Change versus previous monthShort interest in Spyre Therapeutics has recently decreased by 2.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentSpyre Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Spyre Therapeutics this week, compared to 5 articles on an average week.Search Interest2 people have searched for SYRE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,903,193.00 in company stock.Percentage Held by Insiders15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spyre Therapeutics' insider trading history. Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRE Stock News HeadlinesSpyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data PreviewOctober 23, 2026 | finance.yahoo.comSpyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026October 18, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 29 at 1:00 AM | Profits Run (Ad)Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock OfferingOctober 8, 2026 | finance.yahoo.comSpyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below MarketOctober 6, 2026 | finance.yahoo.comSpyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-BellOctober 6, 2026 | finance.yahoo.comSpyre Therapeutics Prices $350 Mln Public Offering Of SharesOctober 6, 2026 | rttnews.comSpyre Therapeutics (NASDAQ:SYRE) Stock: Insider Scott Burrows Sells 7,500 SharesOctober 3, 2026 | insidertrades.comSee More Headlines SYRE Stock Analysis - Frequently Asked Questions How have SYRE shares performed this year? Spyre Therapeutics' stock was trading at $32.76 on January 1st, 2026. Since then, SYRE stock has increased by 202.1% and is now trading at $98.96. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) issued its earnings results on Tuesday, August, 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.40. When did Spyre Therapeutics IPO? Spyre Therapeutics (SYRE) raised $85 million in an initial public offering (IPO) on Wednesday, April 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Who are Spyre Therapeutics' major shareholders? Spyre Therapeutics' top institutional investors include Assenagon Asset Management S.A. (0.59%), Moody Aldrich Partners LLC (0.04%), Profund Advisors LLC (0.03%) and China Universal Asset Management Co. Ltd.. Insiders that own company stock include Cameron Turtle, Scott L Burrows, Michael Thomas Henderson, Sheldon Sloan, Jeffrey W Albers, Heidy King-Jones and Fairmount Funds Management Llc. View institutional ownership trends. How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Taiwan Semiconductor Manufacturing (TSM), IonQ (IONQ), Kratos Defense & Security Solutions (KTOS) and Palantir Technologies (PLTR). Company Calendar Last Earnings8/04/2026Today10/29/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SYRE's financial health is in the Green zone, according to TradeSmith. SYRE has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CIK1636282 Webwww.spyre.com Phone(617) 651-5940Fax512-872-5121Employees112Year Founded2013Price Target and Rating Average Price Target for Spyre Therapeutics$110.40 High Price Target$130.00 Low Price Target$80.00 Potential Upside/Downside+11.6%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$155.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.74% Return on Assets-22.23% Debt Debt-to-Equity RatioN/A Current Ratio18.53 Quick Ratio18.53 Sales & Book Value Annual Sales$890 thousand Price / Sales11,331.48 Cash FlowN/A Price / Cash FlowN/A Book Value$7.21 per share Price / Book13.73Miscellaneous Outstanding Shares101,910,000Free Float85,917,000Market Cap$10.09 billion OptionableOptionable Beta3.10 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SYRE) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
